DSP Healthcare Fund

A Sectoral/Thematic Fund scheme from DSP Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF740KA1LG1).

NAV ₹52.5970 on 13 November 2026.

Expense ratio

Total expense ratio 0.75% a year for the Direct · Growth plan, as AMFI published it on 28 October 2026: base expense ratio 0.53%, brokerage 0.04%, transaction costs 0.00%, statutory levies including GST 0.18%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year19.0%12.7%-10.5%0.941.03
3 years21.4%13.0%-16.1%1.111.05
5 years16.8%13.0%-20.5%0.750.73

Too little NAV history for the 10-year figures.

Category rank: 7th of 13 Direct-Growth funds in Sectoral/Thematic Fund — Pharma, by 3-year Sortino ratio.

Largest holdings

Top 10 (October 2026 disclosure). Company shares make up 97.9% of the portfolio.

  1. Apollo Hospitals Enterprise Limited — 7.89%
  2. IPCA Laboratories Limited — 7.49%
  3. Cipla Limited — 7.40%
  4. Sun Pharmaceutical Industries Limited — 7.32%
  5. Gland Pharma Limited — 6.61%
  6. Sai Life Sciences Limited — 6.17%
  7. Globus Medical Inc (foreign shares) — 5.36%
  8. Alkem Laboratories Limited — 4.73%
  9. Divi's Laboratories Limited — 4.41%
  10. Cohance Lifesciences Limited — 3.82%

Plans

Other funds in Sectoral/Thematic Fund

All 257 funds in Sectoral/Thematic Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.